Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prevalence of Infective Endocarditis in Enterococcus faecalis Bacteremia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Styrene Exposure and Risk of Lymphohematopoietic Malignancies in 73,036 Reinforced Plastics Workers

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
Original languageEnglish
JournalB M C Cancer
Volume10
Pages (from-to)677
ISSN1471-2407
DOIs
Publication statusPublished - 1 Jan 2010

ID: 31055136